# Daniel D. Von Hoff

Source: https://onco.cc/people/daniel-von-hoff/  
OnCo record `daniel-von-hoff` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led the MPACT trial of nab-paclitaxel plus gemcitabine and has run more first-in-human cancer trials than almost anyone.

## Summary

Daniel Von Hoff (TGen and HonorHealth, Phoenix) was principal investigator of MPACT, which established gemcitabine plus nab-paclitaxel as a first-line standard in metastatic pancreatic cancer, and has led the early clinical development of many approved drugs including gemcitabine, irinotecan and vismodegib. He founded one of the largest phase 1 programmes in the United States and was a founding editor of Molecular Cancer Therapeutics.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: pancreatic; early-phase; drug-development
- Role: Distinguished Professor, Translational Genomics Research Institute (TGen); Physician-in-Chief, HonorHealth Research Institute
- Specialisms: Pancreatic cancer; Early drug development; Phase 1 trials; Precision oncology

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Daniel_Von_Hoff
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Von%20Hoff%20DD%5BAuthor%5D%20pancreatic

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- institutions: [Translational Genomics Research Institute (TGen)](https://onco.cc/institutions/tgen/)
- key papers: [MPACT (Von Hoff 2013): nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer](https://onco.cc/key-papers/paper-mpact-nab-paclitaxel-gemcitabine-nejm-2013/), [Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial](https://onco.cc/key-papers/paper-napoli-1-nanoliposomal-irinotecan-lancet-2016/)
- roadmaps: [Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question](https://onco.cc/roadmaps/pancreatic-roadmap/)
- trials: [MPACT](https://onco.cc/trials/mpact/)

---
JSON: https://onco.cc/api/v1/entities/daniel-von-hoff.json